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IMPORTANCE Although surgery offers the best chance of a potential cure for patients with
localized, resectable intrahepatic cholangiocarcinoma (ICC), prognosis of patients remains
dismal largely because of a high incidence of recurrence.
OBJECTIVE To predict very early recurrence (VER) (ie, recurrence within 6 months after
surgery) following resection for ICC in the pre- and postoperative setting.
DESIGN, SETTING, AND PARTICIPANTS Patients who underwent curative-intent resection for
ICC between May 1990 and July 2016 were identified from an international multi-institutional
database. The study was conducted at The Ohio State University in collaboration with all
other participating institutions. The data were analyzed in December 2019.
MAIN OUTCOMES AND MEASURES Two logistic regression models were constructed to predict
VER based on pre- and postoperative variables. The final models were used to develop an
online calculator to predict VER and the tool was internally and externally validated.
RESULTS Among 880 patients (median age, 59 years [interquartile range, 51-68 years]; 388
women [44.1%]; 428 [50.2%] white; 377 [44.3%] Asian; 27 [3.2%] black]), 196 (22.3%)
developed VER. The 5-year overall survival among patients with and without VER was 8.9%
vs 49.8%, respectively (P < .001). A preoperative model was able to stratify patients relative
to the risk for VER: low risk (6-month recurrence-free survival [RFS], 87.7%), intermediate
risk (6-month RFS, 72.3%), and high risk (6-month RFS, 49.5%) (log-rank P < .001). The
postoperative model similarly identified discrete cohorts of patients based on probability for
VER: low risk (6-month RFS, 90.0%), intermediate risk (6-month RFS, 73.1%), and high risk
(6-month RFS, 48.5%) (log-rank, P < .001). The calibration and predictive accuracy of the
pre- and postoperative models were good in the training (C index: preoperative, 0.710;
postoperative, 0.722) as well as the internal (C index: preoperative, 0.715; postoperative,
0.728; bootstrapping resamples, n = 5000) and external (C index: postoperative, 0.672)
validation data sets.
CONCLUSION AND RELEVANCE An easy-to-use online calculator was developed to help
clinicians predict the chance of VER after curative-intent resection for ICC. The tool
performed well on internal and external validation. This tool may help clinicians in the
preoperative selection of patients for neoadjuvant therapy as well as during the
postoperative period to inform surveillance strategies.
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I ntrahepatic cholangiocarcinoma (ICC) ranks as the sec-ond most common primary liver malignancy, with a grow-ing incidence in Western and Eastern countries over the past
3 decades.1,2 Although surgery offers the best chance of a po-
tential cure for patients with localized, resectable ICC, the prog-
nosis of these patients is still discouraging, with a median over-
all survival (OS) ranging from 12 to 31 months.3,4 In fact, 50%
to 70% of patients with ICC will experience a recurrence fol-
lowing resection.5,6
Previous studies defined recurrence following resection
for ICC as early vs late using a cutoff of 2 years.5,6 Patients with
early (<24 months) vs late recurrence (>24 months) had dis-
tinct recurrence patterns, predictors, and outcomes.5,6 Pa-
tients with late recurrence generally had a better prognosis
compared with patients who developed early recurrence fol-
lowing ICC resection.5,7 In addition, certain tumor character-
istics, including tumor size and tumor multifocality, were pre-
dominantly associated with early but not late recurrence.5,7
Although such a categorization (ie, early [<24 months] vs late
[>24 months]) aligns with previous studies on hepatocellular
carcinoma (HCC),8,9 it may not be appropriate for patients with
ICC given that most recurrences occur within the first 2 years
after resection of ICC.5,6 In fact, a previous study from our own
group noted that approximately one-quarter of patients with
ICC had very early recurrence (VER) (ie, recurrence within 6
months after initial resection).5 Patients with VER were even
more common than individuals who experienced a late recur-
rence (>2 years).5 As such, identifying patients who are at risk
for VER is important to construct individualized surveillance
strategies following resection for ICC or even recommend an
alternative treatment strategy for these patients, including neo-
adjuvant therapy or other nonsurgical treatment modalities.
To our knowledge, no predictive tool exists to predict VER
among patients undergoing curative-intent liver resection for
ICC. As such, the objective of this study was to characterize
patients who develop VER following curative-intent resec-
tion for ICC. In addition, we sought to develop preoperative
and postoperative models to predict VER based on factors
known before and after surgery using a large, multi-
institutional database. To facilitate the clinical applicability of
the models, an easy-to-use online calculator was developed
to predict the risk of VER among individuals with resectable
ICC in the pre- and postoperative setting.
Methods
Patient Cohort and Data Collection
Patients who underwent liver resection for histologically
proven ICC between May 1990 and July 2016 were identified
in an international multi-institutional database that incorpo-
rated data from 15 major hepatobiliary institutions involved
in the International Intrahepatic Cholangiocarcinoma
Collaboration.10-12 The VER of ICC was defined as the inci-
dence of recurrence within 6 months after resection based on
previous studies.13-16 Only patients who received curative-
intent hepatectomy were included in the analysis. Patients were
excluded for (1) macroscopically positive surgical margins,
(2) lack of follow-up data, and (3) death or loss to follow-up
without any evidence of recurrence within 6 months follow-
ing resection. The institutional review boards of all the par-
ticipating facilities approved the study. Patient consent was
waived as retrospective deidentified data were analyzed.
Clinicopathologic variables of patients with ICC ex-
tracted included age, sex, race, body mass index (calculated
as weight in kilograms divided by height in meters squared),
cirrhosis, American Society of Anesthesiologists class, preop-
erative serum levels of carcinoembryonic antigen and carbo-
hydrate antigen (CA) 19-9, preoperative lymph node (LN) as-
sessment, tumor size, tumor number, location, macro- or
microvascular invasion, perineural invasion, American Joint
Committee on Cancer (AJCC) tumor stage, AJCC N stage, tu-
mor grade, morphological type (ie, mass-forming, intra-
ductal growth, and periductal infiltrating), extent of resec-
tion, resection margin status, intraoperative blood loss,
operative time, use of perioperative chemotherapy or radio-
therapy, and postoperative complications.5 Major hepatec-
tomy was defined as resection of 3 or more Couinaud
segments.17 Macrovascular invasion was defined as invasion
of the portal vein, hepatic artery, or hepatic veins, whereas mi-
crovascular invasion was defined as intraparenchymal vascu-
lar involvement identified on histology testing results.18 Tu-
mor stage was defined following the AJCC seventh edition
staging manual.
After liver resection, patients were monitored for recur-
rence with serum tumor markers and imaging studies, includ-
ing ultrasonography, computed tomography, and/or mag-
netic resonance imaging. In general, patients were followed up
once every 3 to 4 months for the first 3 years, once every 6
months from years 4 to 5, and then annually.19 Recurrence was
defined as suspicious or positive findings on surveillance
imaging or histologically confirmed disease. The treatment of
tumor recurrence was decided following consensus among the
multidisciplinary team in each institution.
Statistical Analysis
Categorical and continuous variables were presented as fre-
quency (%) and median (interquartile range [IQR]), respec-
Key Points
Question Which patients will develop very early recurrence (VER)
(ie, recurrence within 6 months) after resection for intrahepatic
cholangiocarcinoma and are the best candidates for neoadjuvant
chemotherapy?
Findings In this multi-institutional cohort study, 196 patients
(22.3%) developed VER following resection with a detrimental
association with overall survival (5-year overall survival, 8.9%).
Two predictive models were developed to identify high-risk
patients for VER in the pre- and postoperative setting with a good
predictive accuracy in the training as well as the internal and
external validation data sets.
Meaning These data emphasize that VER is common after
intrahepatic cholangiocarcinoma resection and highlight the need
for an alternative treatment approach (ie, neoadjuvant
chemotherapy) for high-risk patients.
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tively. The association of several clinicopathological factors
with the incidence of VER following ICC resection was as-
sessed by means of logistic regression analysis. Variables sig-
nificant on bivariate analysis were subsequently included in
the multivariable logistic regression model and a stepwise se-
lection method was used (forward selection method using the
lowest bayesian information criterion). Two risk scores to pre-
dict VER of ICC before and after resection were developed based
on the final step of the multivariable logistic regression model.
Specifically, the β coefficients of the risk factors of VER iden-
tified in the final step of the respective multivariable logistic
regression models were used to construct a weighted com-
posite preoperative and postoperative score. Estimated prob-
abilities of developing VER were calculated according to the
following formula: P = 1/{1+exp[−(Preoperative or Postopera-
tive Score)]}, in which P is the probability of developing VER.
For the multivariable logistic regression analysis, multivari-
ate normal imputations were performed for missing data.20 By
using the X-tile program,21,22 the optimal cutoffs of pre- and
postoperative risk scores were determined to stratify pa-
tients at low, intermediate, or high risk for VER.23 In addition,
a model using discrete categorical variables was developed. In
this model, the hazard ratio (HR) of factors that were signifi-
cant in the multivariable model was assigned discrete points
to create a simple scoring system, as previously reported.24 Dif-
ferences in recurrence-free survival (RFS) or OS between dif-
ferent subgroups of patients were assessed using the Kaplan-
Meier method and the log-rank test.
To assess the performance of the prognostic model, the C
index was calculated for the entire data set (training data set)
as well as with the bootstrapping resample method (n = 5000)
(internal validation). Calibration of the models was per-
formed by plotting the predicted probabilities against the ob-
served outcomes of the cohort. The accuracy of the prognos-
tic model to predict VER was also externally validated using
data from the Cleveland Clinic (Cleveland, Ohio) and the First
Affiliated Hospital of Xi'an Jiaotong University (Xi'an, China).
Because of data collection limitations, only the postoperative
VER model was externally validated. The level of statistical sig-
nificance was set at α = .05. To account for the possible asso-
ciation of a period effect, additional sensitivity analyses were
also performed after excluding patients who underwent liver
resection before 2000. All statistical analyses were per-
formed using SPSS, version 25 (IBM), along with JMP statisti-
cal package, version 14 (SAS Institute).
Results
Patient Characteristics With or Without VER
A total of 880 patients met the inclusion criteria and were in-
cluded in the final analytic cohort (Table 1). The median pa-
tient age was 59 years (IQR, 51-68 years), 491 patients (55.9%)
were men, and 562 (70.4%) had an American Society of An-
esthesiologists class of 2 or lower. Most patients underwent a
major hepatectomy (491 [56.9%]) for a T1 or T2 tumor (708
[84.0%]); a subset of patients had LN metastases (165 [18.8%]).
Approximately one-third of patients received adjuvant
chemotherapy or radiotherapy (279 [32.7%]) (Table 1). Over-
all, 196 patients (22.3%) had VER, whereas 684 (77.7%) did not
(non-VER group); 374 patients (42.5%) had a recurrence more
than 6 months after resection and 310 patients (35.3%) did not
experience a recurrence during the follow-up period. Differ-
ences in the characteristics of patients with and without VER
are summarized in Table 1.
Survival and Risk Factors of Patients With VER
After a median follow-up time of 24.1 months (IQR, 13.2-43.6
months), the median and 5-year OS among patients with and
without VER was 13.8 months (IQR, 11.6-15.3 months) and 8.9%
vs 59.7 months (IQR, 48.2-73.8 months) and 49.8%, respec-
tively (P < .001) (Figure 1). On multivariable analysis of pre-
operative factors, race of color (odds ratio [OR], 1.79; 95% CI,
1.23-2.60), liver cirrhosis (OR, 2.06; 95% CI, 1.25-3.40), larger
tumor size (OR, 1.12; 95% CI, 1.06-1.17), higher number of tu-
mors (OR, 1.36; 95% CI, 1.15-1.60), and suspicious/metastatic
LNs on preoperative imaging (OR, 1.90; 95% CI, 1.28-2.84) re-
mained associated with a higher likelihood of VER, whereas
higher age was associated with lower odds of VER (OR, 0.97;
95% CI, 0.96-0.99) (Table 2). A separate multivariable analy-
sis that included all pre- and postoperative factors demon-
strated that race of color (OR, 2.04; 95% CI, 1.38-3.00), larger
tumor size (OR, 1.11; 95% CI, 1.06-1.17), higher number of tu-
mors (OR, 1.36; 95% CI, 1.15-1.60), microvascular invasion (OR,
1.55; 95% CI, 1.06-2.26), N1 or Nx disease (OR, 1.94; 95% CI,
1.29-2.94), and R1 resection (OR, 2.14; 95% CI, 1.27-3.60) were
each associated with greater odds of VER, whereas older age
was again associated with lower odds of VER (OR, 0.97; 95%
CI, 0.95-0.98) (Table 2). Neither hospital location (Eastern vs
Western: OR, 1.33; 95% CI, 0.77-2.30) nor year of surgery (OR,
0.96; 95% CI, 0.92-1.02) were associated with VER. A sensi-
tivity analysis after excluding patients who underwent rere-
section of a recurrent tumor (total number of patients ana-
lyzed, 870 [98.9%]) revealed the same variables were
associated with VER, with only slightly changed ORs com-
pared with the aforementioned models (eTable 1 in the
Supplement).
Development of Preoperative and Postoperative Risk
Scores to Predict VER
Pre- and postoperative risk scores were developed based on
the factors identified in the respective multivariable models
(Table 2). Subsequently, patients were categorized into 3 dif-
ferent risk categories for VER based on the preoperative risk
score: low risk (455 [51.7%]; 6-month RFS, 87.7%), intermedi-
ate risk (332 [37.7%]; 6-month RFS, 72.3%), and high risk (93
[10.6%]; 6-month RFS, 49.5%) (P < .001) (Table 2 and
Figure 2A). Similarly, patients were categorized into 3 differ-
ent risk groups for VER based on the postoperative risk score:
low risk (440 [50.0%]; 6-month RFS, 90.0%), intermediate risk
(308 [35.0%]; 6-month RFS, 73.1%), and high risk (132 [15.0%];
6-month RFS, 48.5%) (P < .001) (Table 2 and Figure 2B). To fa-
cilitate clinical applicability of the preoperative and postop-
erative models, a convenient online calculator able to calcu-
late the probability of VER and the risk group of VER assigned
on the basis of the pre- and postoperative scores was devel-
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Table 1. Comparison of Baseline Characteristics and Operative Variables Between Patients With and Without
Very Early Recurrence Within 6 Months After Curative-Intent Liver Resection for Intrahepatic Cholangiocarcinoma
Variables
No. (%)
P valueTotal (N = 880) VER (n = 196) Non-VER (n = 684)
Age, median (IQR), y 59 (51-68) 55.0 (47-63) 61.0 (52-69) <.001
Sex
Men 491 (55.9) 115 (58.7) 376 (55.1)
.41
Women 388 (44.1) 81 (41.3) 307 (45.0)
Race
White 428 (50.2) 76 (39.8) 352 (53.3)
.007
Asian 377 (44.3) 107 (56.0) 270 (40.9)
Black 27 (3.2) 5 (2.6) 22 (3.3)
Other 20 (2.3) 3 (1.6) 17 (2.6)
BMI, median (IQR) 25 (22.1-27.7) 25.0 (22.5-28.5) 25.0 (22.1-27.6) .53
Liver cirrhosis 95 (12.3) 33 (19.4) 62 (10.3) .002
ASA
≤2 562 (70.4) 135 (73.8) 427 (69.4)
.27
>2 236 (29.6) 48 (26.2) 188 (30.6)
CA 19-9, median (IQR), UI/mL 48.0 (17.8-215.0) 60.9 (26.0-322.0) 44.8 (16.3-182.7) .008
CEA, ng/mL 2.4 (1.5-4.3) 2.8 (1.5-5.3) 2.4 (1.5-3.8) .03
LNM on imaging
Negative 706 (80.2) 143 (73.0) 563 (82.3)
.006
Suspicious or positive 174 (19.8) 53 (27.0) 121 (17.7)
Tumor size, median (IQR), cm 6.0 (4.0-8.3) 7.0 (5.2-9.5) 5.8 (3.9-8.0) <.001
Multiple lesions (≥2) 140 (16.2) 49 (25.3) 91 (13.5) <.001
Bilobar tumor 147 (17.0) 33 (17.1) 114 (17.0) >.99
Macrovascular invasion 100 (11.4) 23 (11.7) 77 (11.3) .90
Microvascular invasion 234 (26.6) 65 (33.2) 169 (24.7) .02
Perineural invasion 136 (17.0) 23 (12.6) 113 (18.3) .07
AJCC tumor category
T1 389 (44.9) 52 (27.8) 314 (50.0)
<.001
T2 319 (39.1) 105 (56.2) 214 (34.1)
T3 96 (11.8) 18 (9.6) 78 (12.4)
T4 34 (4.2) 12 (6.4) 22 (3.5)
AJCC node category
N0 270 (30.7) 42 (21.4) 228 (33.3)
<.001N1 165 (18.8) 52 (26.5) 113 (16.5)
Nx 445 (50.6) 102 (52.0) 343 (50.2)
Histological type
Well to moderate 695 (83.3) 151 (83.0) 544 (83.4)
.12
Poorly to undifferentiated 139 (16.7) 31 (17.0) 108 (16.6)
Morphological type
MF, IG 738 (88.8) 162 (85.7) 576 (89.7)
.15
PI, MF + PI 93 (11.2) 27 (14.3) 66 (10.3)
Resection procedure
Minor 372 (43.1) 91 (47.2) 281 (41.9)
.22
Major 491 (56.9) 102 (52.9) 389 (58.1)
R1 resection 105 (11.9) 32 (16.3) 73 (10.7) .03
Intraoperative blood loss,
median (IQR), ml
400 (200-750) 400 (200-800) 400 (200-750) .77
Duration of surgery,
median (IQR), min
200 (120-316) 173 (116-300) 200 (120-335) .04
Adjuvant
chemotherapy/radiotherapy
279 (32.7) 56 (29.8) 223 (33.5) .38
Postoperative complications 316 (36.3) 65 (33.7) 251 (37.0) .45
Abbreviations: AJCC, American Joint
Committee on Cancer; ASA, American
Society of Anesthesiologists; BMI,
body mass index (calculated as
weight in kilograms divided by height
in meters squared); CA, carbohydrate
antigen; CEA, carcinoembryonic
antigen; IG, intraductal growth; IQR,
interquartile range; LNM, lymph node
metastasis; MF, mass forming; PI,
periductal infiltrating; VER, very early
recurrence.
SI conversion factor: To convert CEA
to μg/L, multiply by 1.
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oped (eFigure 1 in the Supplement), which is available at:
https://k-sahara.shinyapps.io/Veryearly-recurrence/.
Predictive Performance of the Models to Predict VER
The discriminative accuracy of the preoperative model was
very good in the training data set (C index: 0.710; 95% CI, 0.666-
0.750) and the validation data set with bootstrapping resa-
mples (C index: 0.715; 95% CI, 0.700-0.730). Similarly, the pre-
dictive accuracy of the postoperative model was very good in
the training data set (C index: 0.722; 95% CI, 0.677-0.759) as
well as the validation data set with bootstrapping resamples
(C index: 0.728; 95% CI, 0.715-0.742). The calibration plots
demonstrated overall good agreement between the esti-
mated probability of VER and the observed frequency of VER
in the pre- and postoperative models (Figure 3). A sensitivity
analysis was conducted that included only patients who un-
derwent surgery after 2000 (eTable 2 in the Supplement). The
differences in the predicted probability of VER were minor
(0.6% in the pre- and post-operative models).
The postoperative VER model performed well in the ex-
ternal validation cohort (C index: 0.672; 95% CI, 0.595-
0.742). Specifically, patients deemed high risk had a worse RFS
compared with patients who were either intermediate or low
risk for VER (6-month RFS: low risk, 80.4% vs intermediate risk,
75.3% vs high risk, 44.4%; P < .01) (eFigure 2 and eTable 3 in
the Supplement).
Development and Validation of a Simple Scoring System
A simple discrete scoring system was also developed to facili-
tate prognostic classification of patients without the need of
the online calculator (eTable 4 in the Supplement). Specifi-
cally, patients with a preoperative score of 0 to 3, 4 to 5, and 6
to 9 had incrementally worse 6-month RFS (90.1% vs 75.6%
vs 55.2%; P < .001; eFigure 3 in the Supplement). Similarly,
based on the postoperative scoring system, patients with a
score of 0 to 4, 5 to 6, and 7 to 10 had an incrementally worse
6-month RFS (91.1% vs 82.4% vs 57.7%; P < .001; eFigure 3 in
the Supplement); this discrete postoperative scoring system
was also able to stratify patient prognosis in the external vali-
dation cohort (6-month RFS: score of 0-4, 84.3% vs score of
5-6, 72.0% vs score of 7-10, 56.2%; P < .001) (eFigure 4 in the
Supplement). The predictive accuracy of the pre- and postop-
erative models based on the scoring system was also very good
in the training (C index: preoperative, 0.716; postoperative,
0.726) as well as the internal (C index: preoperative, 0.716; post-
operative, 0.725; bootstrapping resamples, n = 5000) and ex-
ternal (C index: postoperative, 0.692) validation data sets.
Treatment and Outcomes of Patients With VER
Among 196 patients who had VER, most had intrahepatic re-
currence only (117 [60.3%]); a subset had extrahepatic recur-
rence (29 [15.0%]) or intra- and extrahepatic recurrence (48
[24.7%]). Among patients with VER, only 10 patients (5.1%) un-
derwent reresection compared with 45 individuals (12.0%)
among those who experienced a later recurrence (P < .001), and
most received the best supportive care (100 [51.0%]) (eTable 5
in the Supplement). The median OS following VER was 9.3
months (95% CI, 8.0–10.5 months). Three-year OS after recur-
rence was better among patients who underwent reresection
vs individuals who received other types of treatment (54.0%
vs 13.0%; P = .001) (eFigure 5 in the Supplement).
Discussion
Several previous studies have used the term VER to charac-
terize recurrence within 6 months following resection for HCC
and colorectal liver metastases.14-16 Although there is no con-
sensus about the exact timing of early recurrence among pa-
tients with ICC, using a cutoff of 2 years for ICC may be prob-
lematic because many patients with ICC have recurrence much
earlier within the very first months following resection.5 This
study demonstrated that approximately one-fourth of pa-
tients (22.3%) developed recurrence within 6 months after re-
section for ICC. Patients with a VER had a median OS as low
as 13.8 months, which is similar to patients with advanced cho-
langiocarcinoma who received systemic chemotherapy in a
phase 3 randomized clinical trial (median OS, 11.7 months).25
In addition, 2 models, one preoperative and one postopera-
tive, were developed to calculate the risk of VER among pa-
tients with resectable ICC. Using the preoperative model, pa-
tients were categorized into low- (455 [51.7%]), intermediate-
(332 [37.7%]), and high-risk groups (93 [10.6%]) with an incre-
mentally worse 6-month RFS (87.7% vs 72.3% vs 49.5%;
P < .001). Similarly, a postoperative model identified 3 groups
of patients with an incrementally worse RFS (6-month RFS:
90.0% vs 73.1% vs 48.5%; P < .001). Using an online calcula-
tor developed in this study, physicians can calculate the indi-
vidualized possibility of patients to develop VER in the pre-
and postoperative setting. An additional simple discrete scor-
ing system to predict VER was developed and validated that
can be used by physicians without requiring the use of an on-
line calculator. To our knowledge, this is the first study to de-
fine the incidence and risk of VER as well as provide a predic-
tion tool to assess the likelihood of VER among patients
undergoing surgery for ICC.
Figure 1. Kaplan-Meier Curve Demonstrating the Differences
in Overall Survival Between Patients With and Without
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This study developed 2 models to predict VER following
resection for ICC. Based on variables, such as age, race, liver
cirrhosis, tumor size and number, and radiologic LN status,
the preoperative model was able to identify 3 groups of
patients with different risk for VER (ie, low-, intermediate-,
and high-risk groups) who had an incrementally worse
6-month RFS (87.7 % vs 72.3% vs 49.5%; P < .001)
(Figure 2A). Incorporating pathologic data, including micro-
vascular invasion, nodal status, and resection margins, the
postoperative model was able to stratify patients according
to risk for VER (90.0% vs 73.1% vs 48.5%; P < .001). Tumor
size and number (eg, tumor burden),26 microvascular and
nodal invasion,6 liver cirrhosis, and resection margins have
been associated with risk of recurrence among patients with
Table 2. Bivariate and Multivariable Logistic Regression Analyses of Factors Associated With Very Early Recurrence in Patients




Preoperative model Postoperative model
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Age 0.96 (0.95-0.98) <.001 0.97 (0.96-0.99) <.001 0.97 (0.95-0.98) <.001
Race




Person of color 1.70 (1.23-2.34) .001 1.79 (1.23-2.60) 2.04 (1.38-3.00)
Liver cirrhosis 2.03 (1.29-3.21) .002 2.06 (1.25-3.40) .005 NA
Ln CA19-9 1.11 (1.02-1.22) .02 NA
Tumor size (cm) 1.10 (1.06-1.15) <.001 1.12 (1.06-1.17) <.001 1.11 (1.06-1.17) <.001
No. of lesions 1.37 (1.18-1.58) <.001 1.36 (1.15-1.60) <.001 1.36 (1.15-1.60) <.001






Suspicious or positive 1.72 (1.19-2.50) 1.90 (1.28-2.84)
AJCC N category
N0 1 [Reference] NA
NA NA
1 [Reference] NA
N1 or Nx 1.83 (1.26-2.67) .001 1.94 (1.29-2.94) .001
R1 margin 1.63 (1.04-2.56) .03 2.14 (1.27-3.60) .005
Abbreviations: AJCC, American Joint Committee on Cancer; Ln, natural
logarithm; LNM, lymph node metastasis.
a Prescore = 1.911 − 0.030 × Age + 0.581 × (Race, Nonwhite: 1; White:
0) + 0.724 × (Cirrhosis: Yes: 1; No: 0) + 0.111 × Size (cm) +0.304 × Number of
Lesions +0.643 × (LNM on Imaging Suspicious or Positive: 1, Negative: 0). For
the determination of cutoffs based on the prescore, please use: low, 1.77 or
less; intermediate, more than 1.77 to 2.69 or less; high, more than 2.69.
Postscore = 1.811 − 0.032 × Age + 0.711 × (Race: Nonwhite, 1; White,
0) + 0.104 × Size (cm) + 0.307 × Number of Lesions + 0.665 × (N Stage N1 or
Nx: 1; N0: 0) + 0.436 (Microvascular Invasion: Yes, 1; No, 0) + 0.759 (Surgical
Margin: R1, 1; R0, 0). For the determination of cutoffs based on the postscore,
please use: low, 2.02 or less; intermediate, more than 2.02 to 2.80 or less; and
high, more than 2.80.
Figure 2. Kaplan-Meier Curves Demonstrating the Differences in Recurrence-Free Survival Among Low-, Intermediate-, and High-Risk Patients
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ICC.10,27 In contrast, data on age as a predictor of outcomes
among patients with cancer have been more equivocal.3,28
In this study, younger age remained associated with a
higher chance for VER in the pre- and postoperative models.
Although the explanation is likely multifactorial, the
increased proliferative and angiogenic activity of tumor
cells in younger individuals may be significantly associated
with recurrence rates.29 The presence of cirrhosis was only
included in the preoperative predictive model; the former
did not remain associated with VER after accounting for
other variables available during the postoperative period
(eg, vascular invasion). In addition, suspicious or metastatic
LNs on preoperative imaging were replaced in the postop-
erative model with actual pathologic nodal status. Taken
together, the data highlight how patients with multiple nod-
ules, large tumor size, and suspicious or metastatic LNs on
preoperative imaging have a markedly higher likelihood of
experiencing VER and, in turn, a poor survival.11 Thus, iden-
tifying patients who are likely to experience a VER is par-
ticularly important because these patients should be consid-
ered for clinical trials, neoadjuvant therapy, or other
nonsurgical treatment modalities. In addition, characteriz-
ing patients at risk for VER in the postoperative setting may
be useful in determining the intensity of the surveillance
strategy, as well as identifying patients who might benefit
more from adjuvant chemotherapy following resection of
ICC.
The finding that 1 in 4 patients experienced VER with an
overall survival of roughly 1 year after surgery was particu-
larly notable. These data were comparable with outcomes
among many patients with pancreatic adenocarcinoma who
often have recurrence early and have a very poor survival
rate.30 Because of these poor outcomes, there has been a
marked increase over the last decade in the routine use of neo-
adjuvant chemotherapy among patients with pancreatic
cancer.31 Neoadjuvant therapy is used for many reasons,
including early treatment of micrometastatic disease, in ad-
dition to treatment of the index lesion.32 In this manner, early
systemic chemotherapy provides a therapeutic and selection
role to help determine which patients may benefit most from
an attempt at curative-intent surgery.33 In fact, neoadjuvant
therapy has been demonstrated to be effective in increasing
disease-free survival among patients with pancreatic and peri-
hilar cholangiocarcinoma.34,35 Despite this, the use of neoad-
juvant therapy among patients with ICC remains extremely
low.36 However, more recently, epidermal growth factor re-
ceptor signaling pathway, as well as isocitrate dehydrogenase
mutations, have been identified as specific therapeutic tar-
gets for systemic therapy.37,38 Therefore, use of the VER tool
may be important to inform a potential paradigm shift in treat-
ing patients with ICC. Specifically, by using the tool proposed
in this study (https://k-sahara.shinyapps.io/Veryearly-
recurrence/), surgeons can estimate the individualized risk of
a specific patient to experience VER. In addition, by using the
simple scoring system developed in this study, physicians can
also estimate the risk of VER without requiring the use of an
online calculator (eTable 4 and eFigures 3 and 4 in the
Supplement). In turn, patients at high risk for VER should be
considered candidates for clinical trials, neoadjuvant systemic
chemotherapy, or alternative liver-directed treatment options
rather than upfront surgery.
Limitations
Several limitations should be considered when interpreting
the results of this study. While the multi-institutional
nature of the database was a strength, there may have been
some heterogeneity in patient selection and surgical tech-
niques among the different participating centers. The dura-









































Estimated probability of VER
Preoperative modelA
0.5 0.60 0.1 0.2 0.3 0.4
Estimated probability of VER
Postoperative modelB
0.5 0.60 0.1 0.2 0.3 0.4
The dots represent the deciles of patients’ observed frequency of VER plotted against the estimated/predicted probability of VER. The smooth lines are cubic
splines representing the relationship between the frequency and the predicted probability of VER.
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tion of the cohort may have also contributed to a period
effect and associated heterogeneity; however, a sensitivity
analysis that excluded patients who underwent an opera-
tion before 2000 (n = 33) demonstrated similar results.
In addition, data on CA19-9 levels 1 month after surgery
were not available in the data set and we were thus unable
to assess whether this information could predict VER fol-
lowing liver resection of ICC. However, not all patients with
ICC express CA19-9 and the more comprehensive postop-
erative model developed in the context of this study did
predict VER well in the test and external validation cohorts.
Information on α-fetoprotein levels was also not available in
the database because most centers routinely measure
CA19-9 and not α-fetoprotein for ICC patients; all patients
underwent resection for pure ICC and none had mixed HCC-
ICC. Furthermore, there may have been slight variations in
radiologic or pathologic assessment of tumor size and num-
ber at different centers depending on the method of assess-
ment; however, these are unlikely to be clinic ally
significant.23
Conclusions
Approximately one-fourth of patients undergoing curative-
intent hepatectomy for ICC developed VER, which was asso-
ciated with a very discouraging prognosis. An easy-to-use on-
line calculator to predict the risk of VER was developed based
on clinicopathological variables available before and after re-
section for ICC. The VER calculator demonstrated a very good
accuracy on internal and external validation. The online cal-
culator may help clinicians to use neoadjuvant therapy more
often among high-risk patients with ICC as well as inform the
intensity of surveillance following resection.
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